“…Intriguingly, regulators of the m7G modification are aberrantly expressed in various cancers and may act as novel biomarkers for diagnosis and prognostic prediction. The m7G regulator METTL1 is significantly overexpressed and promotes tumorigenesis and development in AML, BC, ESCC, glioma, HCC, HNSCC, ICC, LC, and NPC, and high expression levels of METTL1 often predict poor survival in these patients [ 26 , 43 , 52 , 56 , 59 , 60 , 66 , 68 , 78 ]. WDR4 is also highly expressed and increases malignant phenotypes in multiple malignancies, including AML, ESCC, HCC, HNSCC, IC, LC, and NPC.…”